Chemotherapy side effects lead to discontinuation, influencing a shift towards palliative care over treatment.
Antibody-drug conjugates (ADCs) show promise in selectively targeting cancer cells with less toxicity, requiring a complex understanding of cancer biology for development.
Decades of work have led to the development of ADCs, aiming to be more effective and have fewer side effects compared to conventional chemotherapy.
Early ADCs were ineffective and highly toxic, but improvements in design have led to FDA approval for certain treatments.
Collection
[
|
...
]